HUTCHMED China Ltd (0013.HK)
Company Info
Highlights
HK$20.52B
77.42
HK$18.36 - HK$35.90
HK$38.82
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in HUTCHMED China Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
HUTCHMED China Ltd (0013.HK) returned 1.12% year-to-date (YTD) and -26.82% over the past 12 months.
0013.HK
1.12%
13.25%
-21.08%
-26.82%
N/A
N/A
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of 0013.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -6.70% | 23.21% | -7.38% | -2.73% | -2.37% | 1.12% | |||||||
| 2024 | -31.22% | 22.59% | 10.54% | 13.08% | -2.64% | -6.62% | 10.00% | -8.26% | 16.04% | -11.80% | -6.69% | -15.47% | -21.95% |
| 2023 | 20.00% | -10.24% | -20.12% | 16.46% | -21.00% | -2.95% | 24.73% | 4.78% | 10.58% | 17.82% | -3.82% | -4.97% | 19.58% |
| 2022 | -28.04% | 5.27% | -29.92% | -14.62% | -34.71% | 15.26% | 2.59% | -1.71% | -32.21% | -0.15% | 62.50% | 11.89% | -57.67% |
| 2021 | 17.08% | -17.00% | -2.73% | -18.77% | 20.95% | 1.25% | -5.97% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 0013.HK is 30, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for HUTCHMED China Ltd (0013.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the HUTCHMED China Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the HUTCHMED China Ltd was 84.85%, occurring on Oct 24, 2022. The portfolio has not yet recovered.
The current HUTCHMED China Ltd drawdown is 70.81%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.85% | Jul 30, 2021 | 305 | Oct 24, 2022 | — | — | — |
| -15.14% | Jul 23, 2021 | 3 | Jul 27, 2021 | 2 | Jul 29, 2021 | 5 |
| -13.73% | Jul 5, 2021 | 3 | Jul 7, 2021 | 10 | Jul 21, 2021 | 13 |
Volatility
Volatility Chart
The current HUTCHMED China Ltd volatility is 31.21%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of HUTCHMED China Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how HUTCHMED China Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 0013.HK, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 0013.HK has a P/E ratio of 77.4. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 0013.HK compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 0013.HK currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 0013.HK relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 0013.HK has a P/S ratio of 32.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 0013.HK in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 0013.HK has a P/B value of 3.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |